CDX 1307

Drug Profile

CDX 1307

Alternative Names: CDX-1307; MDX-1307

Latest Information Update: 17 Feb 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Medarex
  • Developer Celldex Therapeutics Inc
  • Class Immunotherapies; Monoclonal antibodies; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Bladder cancer; Breast cancer; Colorectal cancer; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 17 Feb 2012 Discontinued - Phase-I for Breast cancer in USA (Intradermal)
  • 17 Feb 2012 Discontinued - Phase-I for Breast cancer in USA (IV)
  • 17 Feb 2012 Discontinued - Phase-I for Colorectal cancer in USA (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top